CalciMedica’s Auxora shows efficacy in presentation

CalciMedica announced that there will be a presentation of data from the initial cohort of the CRSPA study of Auxora in asparaginase-induced pancreatic toxicity at the 65th Annual American Society of Hematology Meeting & Exposition December 9-12 in San Diego. The data to be presented by the study sponsor highlights promising early results of the investigational use of Auxora in children with acute lymphoblastic leukemia experiencing asparaginase-associated pancreatitis. The presentation includes results from the first cohort consisting of nine patients from the CRSPA study. Treatment with Auxora compared to the historical matched control group reduced the average number of days patients spent in the hospital from 13.4 to 6.3 days. Three control patients needed intensive care unit care compared to one treated patient and average number of days in the ICU was reduced from 5 to 3 days. Additionally, no CRSPA patients required total parenteral nutrition vs. 68.8% in the historical matched control group. Based on the results from cohort 1 of CRSPA, a dose level 1 has been established as the recommended dose of Auxora for children with ALL experiencing AIPT.